8% Off
Utromeg25 mg
Unimed Unihealth MFG. Ltd.
৳276.00
Add to cart
Generic medicine
Mirabegron: Brands, Price & Uses in Bangladesh
Established (FDA-Approved) Indications Overactive bladder (OAB) in adults — for the treatment of symptoms of urge urinary incontinence, urgency, and urinary frequency.
About Mirabegron
Indications of Mirabegron
Established (FDA-Approved) Indications
- Overactive bladder (OAB) in adults — for the treatment of symptoms of urge urinary incontinence, urgency, and urinary frequency. Mirabegron may be used as monotherapy or in combination with the anticholinergic agent solifenacin succinate when monotherapy with either agent provides inadequate control of symptoms.
- Neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older — Mirabegron extended-release tablets (patients weighing ≥35 kg) or oral suspension granules (patients weighing ≥11 kg) are approved for this indication, generally used together with clean intermittent catheterization.
Not an Approved Use
Mirabegron is not approved for treatment of overactive bladder in pediatric patients (its pediatric approval is limited to neurogenic detrusor overactivity) and is not indicated for stress urinary incontinence.
Dosage & Administration of Mirabegron
Overactive Bladder (Adults)
| Step | Dose |
|---|---|
| Starting dose | 25 mg orally once daily, with or without food |
| Dose increase | May increase to 50 mg once daily after 4–8 weeks, based on individual efficacy and tolerability |
Extended-release tablets should be swallowed whole with liquid and should not be chewed, divided, or crushed.
Neurogenic Detrusor Overactivity (Pediatric, ≥3 years)
| Body weight | Dosing |
|---|---|
| 11 kg to <22 kg | Oral suspension granules, weight-based starting and maximum dose per prescriber guidance |
| 22 kg to <35 kg | Oral suspension granules, weight-based starting and maximum dose per prescriber guidance |
| ≥35 kg | Extended-release tablet or oral suspension granules, starting at the lowest approved dose with possible increase after 4–8 weeks |
Pediatric dosing of Mirabegron must be individualized and supervised by a physician experienced in managing neurogenic detrusor overactivity, generally alongside clean intermittent catheterization.
Dose Adjustment in Organ Impairment
| Impairment | Recommendation |
|---|---|
| Renal, eGFR 30–89 mL/min/1.73m² | No dose adjustment required |
| Renal, eGFR 15–29 mL/min/1.73m² | Maximum 25 mg once daily |
| Renal, eGFR <15 mL/min/1.73m² or end-stage renal disease | Use of Mirabegron is not recommended |
| Hepatic, mild (Child-Pugh A) | No dose adjustment required |
| Hepatic, moderate (Child-Pugh B) | Maximum 25 mg once daily |
| Hepatic, severe (Child-Pugh C) | Use of Mirabegron is not recommended |
Take Mirabegron exactly as prescribed by your physician; do not increase the dose on your own, and inform your physician of any missed doses.
Side Effects of Mirabegron
The following side effects have been reported with Mirabegron in clinical trials.
Common Side Effects (Monotherapy)
- Hypertension (increased blood pressure)
- Nasopharyngitis (common cold symptoms)
- Urinary tract infection
- Headache
Common Side Effects (Combination Therapy with Solifenacin)
- Dry mouth
- Constipation
- Tachycardia (fast heart rate)
Less Common but Serious Side Effects
- Urinary retention (see Precautions and Warnings)
- Angioedema of the face, lips, tongue, and/or larynx (see Precautions and Warnings)
- Atrial fibrillation (reported rarely)
Contraindications of Mirabegron
Mirabegron is contraindicated in patients with known hypersensitivity to Mirabegron or any component of the formulation.
Frequently Asked Questions about Mirabegron
What is Mirabegron used for?
Mirabegron is used to treat overactive bladder (OAB) in adults, including symptoms of urgency, frequency, and urge urinary incontinence. In children aged 3 years and older, Mirabegron is used to treat neurogenic detrusor overactivity, usually alongside clean intermittent catheterization.
How is Mirabegron different from other overactive bladder medicines?
Unlike anticholinergic (antimuscarinic) drugs commonly used for overactive bladder, Mirabegron works through a different mechanism — it stimulates beta-3 adrenergic receptors to relax the bladder muscle — so it may cause less dry mouth and constipation, though it carries its own risks such as increased blood pressure.
Can Mirabegron raise blood pressure?
Yes, Mirabegron can increase blood pressure and is not recommended in patients with severe uncontrolled hypertension (blood pressure ≥180/110 mmHg). Blood pressure should be checked before starting and periodically during treatment with Mirabegron, especially in patients with a history of high blood pressure.
Is Mirabegron safe during pregnancy or breastfeeding?
Safety data for Mirabegron in human pregnancy and breastfeeding are limited. Mirabegron should be used during pregnancy or lactation only if clearly needed and the potential benefit justifies the potential risk; always consult a physician before using Mirabegron in these situations.
What should I tell my doctor before starting Mirabegron?
Tell your doctor if you have high blood pressure, kidney or liver problems, difficulty emptying your bladder, or if you are taking other medicines for overactive bladder or drugs affected by CYP2D6 (such as certain antidepressants, antipsychotics, or beta-blockers), since Mirabegron can interact with these.
What if I miss a dose or take too much Mirabegron?
If you miss a dose of Mirabegron, take your next dose at the regular time; do not double the dose. If you suspect an overdose of Mirabegron, seek immediate medical attention or contact a poison control center, as an overdose can cause palpitations and a fast heart rate.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.